The administrative core will provide essential support for all administrative activities associated with the program project grant or al| Project and Cores. The administrative core will provide support for accounting, budgeting, fiscal reporting, protocol submission, dissemination of information between program sites, as well as preparation and distribution of protocol revisions and yearly renewal reporting. Protocol monitoring, data coordination, and communication among project and core key personnel through in-person meetings, regularly scheduled conference calls, and additional telephone communication will be the responsibility of the administrative core. Additionally, the core will support scheduling and coordination of internal research meetings and external consultant visits. The Core with centrally coordinate sample and clinical materials distribution between Projects, participating clinical sites and Cores. The Core will also support clinical trials by coordination of research nurse support at the University site for the therapeutic trials in Projects 2 and 3 and the prospective trials in Project 3.
The administrative and clinical support core will function to make the group cohesive and integrated. This will be accomplished by promoting communication, external review ofthe program, central data collection and i safety monitoring and sample dissemination.
|Presnell, S R; Al-Attar, A; Cichocki, F et al. (2015) Human natural killer cell microRNA: differential expression of MIR181A1B1 and MIR181A2B2 genes encoding identical mature microRNAs. Genes Immun 16:89-98|
|Cichocki, Frank; Schlums, Heinrich; Li, Hongchuan et al. (2014) Transcriptional regulation of Munc13-4 expression in cytotoxic lymphocytes is disrupted by an intronic mutation associated with a primary immunodeficiency. J Exp Med 211:1079-91|
|Cooley, Sarah; Weisdorf, Daniel J; Guethlein, Lisbeth A et al. (2014) Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia. J Immunol 192:4592-600|
|Bachanova, Veronika; Miller, Jeffrey S (2014) NK cells in therapy of cancer. Crit Rev Oncog 19:133-41|
|Foley, Bree; Felices, Martin; Cichocki, Frank et al. (2014) The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT). Immunol Rev 258:45-63|
|Miller, Jeffrey S; Rooney, Cliona M; Curtsinger, Julie et al. (2014) Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy. Biol Blood Marrow Transplant 20:1252-7|
|Felices, Martin; Lenvik, Todd R; Ankarlo, Dave E M et al. (2014) Functional NK cell repertoires are maintained through IL-2R? and Fas ligand. J Immunol 192:3889-97|
|Gleason, Michelle K; Ross, Julie A; Warlick, Erica D et al. (2014) CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood 123:3016-26|
|Sarkar, Chandrima; Cooley, Sarah; Srivastava, Jaideep (2014) Robust Feature Selection Technique using Rank Aggregation. Appl Artif Intell 28:243-257|
|Bachanova, Veronika; Cooley, Sarah; Defor, Todd E et al. (2014) Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood 123:3855-63|
Showing the most recent 10 out of 44 publications